ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 80.45 |
| Open | 80.54 |
| Bid | 80.84 x 800 |
| Ask | 81.05 x 800 |
| Day's Range | 80.54 - 84.66 |
| 52 Week Range | 60.27 - 153.99 |
| Volume | 550,075 |
| Avg. Volume | 926,327 |
| Market Cap | 8.211B |
| Beta (3Y Monthly) | 2.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.97 |
| Earnings Date | Feb 6, 2019 - Feb 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 121.61 |
- GlobeNewswire•8 hours ago
New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, Jan. 16, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Markit•yesterday
See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
# Alnylam Pharmaceuticals Inc ### NASDAQ/NGS:ALNY View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing ## Bearish sentiment Short interest | Neutral Short interest is moderate for ALNY with between 5 and 10% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 11. ## Money flow ETF/Index ownership | Positive ETF activity is positive but appears to be weakening. Over the last month, growth of ETFs holding ALNY is favorable, with net inflows of $7.72 billion. This is among the highest periods of net inflows seen over the last one-year, but the rate of additional flows appears to be decreasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•yesterday
Pfizer Gets FDA's Priority Review for Rare Disease Candidate
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
- Business Wire•2 days ago
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.50 per share. The gross proceeds to Alnylam from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $387,500,000. The offering is expected to close on or about January 17, 2019, subject to the satisfaction of customary closing conditions.
- Investor's Business Daily•2 days ago
This Biotech Stock Plunged On Its Looming Rivalry With Pfizer
Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.
- Business Wire•2 days ago
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter a 30-day option to purchase up to an additional 750,000 shares of its common stock solely to cover over-allotments. Barclays Capital Inc. is acting as sole book-running manager for the offering.
- Zacks•7 days ago
Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus
It was a busy week for the biotech sector with most companies gaining on M&A activity. The annual J.P. Morgan Healthcare conference were also a key area of focus.
- Motley Fool•8 days ago
3 Things Alnylam's Management Wants You to Know
The biotech gave investors reasons to cheer at the J.P. Morgan Healthcare Conference
- Zacks•8 days ago
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
- American City Business Journals•9 days ago
Sales of Alnylam's first drug beat expectations in final quarter of 2018
The announcement commanded investor's attention to kick off the weeklong JP Morgan Healthcare conference.
- Business Wire•9 days ago
Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today pre-announced its unaudited fourth quarter 2018 global net product revenues for ONPATTRO and provided additional updates on the product’s commercial launch. ONPATTRO global net product revenues (unaudited) for the fourth quarter of 2018 were $11-12 million. As of year-end 2018, over 200 patients in the U.S. and EU were receiving commercial ONPATTRO treatment, and approximately 550 total patients worldwide, including patients on commercial drug and patients in clinical studies and in the Company’s global Expanded Access Program (EAP), were being treated with patisiran.
- Investor's Business Daily•14 days ago
Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018
The Food and Drug Administration approved 59 new drugs in 2018 — hitting at least a four-year record — though fewer biologic drugs passed muster. There were also 17 biologic drugs approved.
Markit•15 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•19 days ago
Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter 2018 global net product revenues for ONPATTRO® (patisiran) as well as additional updates on the product’s commercial launch. In addition, the Company will webcast the Q&A breakout session immediately following its presentation at 11:00 am PT (2:00 pm ET).
- Zacks•20 days ago
Alnylam (ALNY) Surges: Stock Moves 8.7% Higher
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Markit•23 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on December 20. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
- Business Wire•27 days ago
Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Alnylam Pharmaceuticals, Inc. have sued Alnylam officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 and September 12, 2018.
- Motley Fool•29 days ago
RNAi Goes Big-Time in 2018
A first-in-kind FDA approval catapulted this treatment approach into the spotlight.
- Benzinga•29 days ago
Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
Health care stocks are among a handful of sectors bucking the broader market downturn in 2018. Biotechs, though down for the year, have suffered less damage than other stocks. One factor that worked in ...
- Motley Fool•last month
Top 10 Healthcare Stories of 2018
New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma
NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working ...
Zacks•last month5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
- Business Wire•last month
Alnylam Announces Settlement of Litigation with Silence Therapeutics
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multiple countries. Under terms of the global settlement, Silence will receive a low royalty on annual net sales of ONPATTRO in the EU only, with tiered royalties of 0.33 percent to 1.0 percent through 2023. Further terms of the agreement include the grant from Silence to Alnylam of a non-exclusive, global irrevocable, license to all relevant patents and for all current and future Alnylam products, whether commercialized by Alnylam or a collaborator or licensee (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and all other investigational therapeutics in Alnylam’s current and future pipeline).
- Insider Monkey•last month
Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- The Wall Street Journal•last month
[$$] Moderna IPO Marks Milestone for New Biotech Market
Inc.’s $604.3 million initial public offering is a highlight in a big year for the new field of messenger-RNA therapeutics. Moderna, whose drugs and vaccines are designed to cause cells to produce molecules that treat or prevent disease, went public at $23 a share late Thursday and began trading Friday at $22. Alnylam, valued at $7.38 billion, this year became the first to win U.S. approval for a product in a class of treatments, known as siRNA therapy, which silence disease-causing RNA molecules.
